过敏疫苗市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按过敏类型、疫苗类型、按应用程式、最终用户、地区和竞争细分

2022年全球过敏疫苗市场价值为13.3亿美元，预计到2028年预测期内将出现令人印象深刻的成长，复合CAGR为8.20%。全球过敏疫苗市场是指涉及开发、生产的製药业领域和分发过敏疫苗，也称为过敏原免疫疗法。过敏疫苗旨在透过使患者的免疫系统对花粉、尘螨或昆虫毒液等特定过敏原脱敏来治疗过敏性疾病。这种疗法通常透过注射或舌下含片进行给药，旨在减轻过敏反应的严重程度并改善患者的生活品质。

主要市场驱动因素

过敏症盛行率增加

市场概况
预测期	2024-2028
2022 年市场规模	13.3亿美元
2028 年市场规模	21.2亿美元
2023-2028 年CAGR	8.20%
成长最快的细分市场	医院
最大的市场	北美洲

过敏不再是小众健康问题；它们已成为一种全球流行病，影响着数以百万计的各个年龄层的人。过敏盛行率的增加不仅是公共卫生问题，也是全球过敏疫苗市场蓬勃发展的重要动力。过敏原免疫疗法或过敏疫苗为过敏患者带来了希望，随着过敏率持续飙升，这些创新疗法的市场必将扩大。

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 涵盖的市场
  • 考虑学习的年份
  • 主要市场区隔

第 2 章：研究方法

• 研究目的
• 基线方法
• 主要产业伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量与验证
• 假设和限制

第 3 章：执行摘要

• 市场概况
• 主要市场细分概述
• 主要市场参与者概述
• 重点地区/国家概况
• 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球过敏疫苗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依过敏类型（过敏性气喘、猫皮屑过敏、草花粉过敏、花生过敏、季节性过敏性鼻炎、树花粉过敏）
  • 依疫苗类型（猫过敏疫苗、屋尘螨过敏疫苗、注射型 MPL 过敏疫苗、花生过敏疫苗、豚草过敏免疫治疗疫苗）
  • 按应用（HIV、肿瘤学、呼吸系统）
  • 按最终使用者（家庭护理、医院、专科诊所、其他）
  • 按地区
  • 按公司划分 (2022)
• 产品市场地图
  • 按过敏类型
  • 按疫苗类型
  • 按应用
  • 按最终用户
  • 按地区

第 6 章：北美过敏疫苗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依过敏类型（过敏性气喘、猫皮屑过敏、草花粉过敏、花生过敏、季节性过敏性鼻炎、树花粉过敏）
  • 依疫苗类型（猫疫苗、屋尘螨疫苗、注射 MPL 疫苗、花生疫苗、豚草过敏免疫治疗疫苗）
  • 按应用（HIV、肿瘤学、呼吸系统）
  • 按最终使用者（家庭护理、医院、专科诊所、其他）
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 7 章：欧洲过敏疫苗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依过敏类型（过敏性气喘、猫皮屑过敏、草花粉过敏、花生过敏、季节性过敏性鼻炎、树花粉过敏）
  • 依疫苗类型（猫疫苗、屋尘螨疫苗、注射 MPL 疫苗、花生疫苗、豚草过敏免疫治疗疫苗）
  • 按应用（HIV、肿瘤学、呼吸系统）
  • 按最终使用者（家庭护理、医院、专科诊所、其他）
  • 按国家/地区
• 欧洲：国家分析
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙

第 8 章：亚太地区过敏疫苗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依过敏类型（过敏性气喘、猫皮屑过敏、草花粉过敏、花生过敏、季节性过敏性鼻炎、树花粉过敏）
  • 依疫苗类型（猫疫苗、屋尘螨疫苗、注射 MPL 疫苗、花生疫苗、豚草过敏免疫治疗疫苗）
  • 按应用（HIV、肿瘤学、呼吸系统）
  • 按最终使用者（家庭护理、医院、专科诊所、其他）
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国

第 9 章：南美洲过敏疫苗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依过敏类型（过敏性气喘、猫皮屑过敏、草花粉过敏、花生过敏、季节性过敏性鼻炎、树花粉过敏）
  • 依疫苗类型（猫疫苗、屋尘螨疫苗、注射 MPL 疫苗、花生疫苗、豚草过敏免疫治疗疫苗）
  • 按应用（HIV、肿瘤学、呼吸系统）
  • 按最终使用者（家庭护理、医院、专科诊所、其他）
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第10章：中东和非洲过敏疫苗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依过敏类型（过敏性气喘、猫皮屑过敏、草花粉过敏、花生过敏、季节性过敏性鼻炎、树花粉过敏）
  • 依疫苗类型（猫过敏疫苗、屋尘螨过敏疫苗、注射型 MPL 过敏疫苗、花生过敏疫苗、豚草过敏免疫治疗疫苗）
  • 按应用（HIV、肿瘤学、呼吸系统）
  • 按最终使用者（家庭护理、医院、专科诊所、其他）
  • 按国家/地区
• MEA：国家分析
  • 南非过敏疫苗
  • 沙乌地阿拉伯过敏疫苗
  • 阿联酋过敏疫苗
  • 科威特过敏疫苗

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 13 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第14章：竞争格局

• 商业概览
• 产品供应
• 最近的发展
• 财务（据报导）
• 主要人员
• SWOT分析
  • Stallergenes Greer PLC
  • Allergy Therapeutics PLC
  • HAL Allergy BV
  • Jubilant HollisterStier Allergy
  • Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
  • Dermapharm AG
  • Merck KGaA
  • Aimmune Therapeutics Inc

第 15 章：策略建议

第 16 章：关于我们与免责声明

Global Allergy Vaccine Market has valued at USD 1.33 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.20% through 2028. The global allergy vaccine market refers to the pharmaceutical industry segment that deals with the development, production, and distribution of allergy vaccines, also known as allergen immunotherapy. Allergy vaccines are designed to treat allergic conditions by desensitizing the patient's immune system to specific allergens, such as pollen, dust mites, or insect venom. This therapy is typically administered through injections or sublingual tablets, and it aims to reduce the severity of allergic reactions and improve patients' quality of life.

Key Market Drivers

Increasing Prevalence of Allergies

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 1.33 Billion
Market Size 2028	USD 2.12 Billion
CAGR 2023-2028	8.20%
Fastest Growing Segment	Hospitals
Largest Market	North America

Allergies are no longer a niche health concern; they have become a global epidemic, affecting millions of people of all ages. This increasing prevalence of allergies is not just a matter of public health but also a significant driver behind the burgeoning global allergy vaccine market. Allergen immunotherapy, or allergy vaccines, offer a beacon of hope for those suffering from allergies, and as allergy rates continue to soar, the market for these innovative treatments is set to expand.

In recent years, the prevalence of allergies has witnessed a remarkable surge across the globe. Allergic conditions, including allergic rhinitis, asthma, food allergies, and eczema, are no longer limited to specific regions but have become a worldwide concern. This can be attributed to various factors such as environmental changes, urbanization, dietary patterns, and genetic predispositions.

The traditional approach to allergy management, which primarily involves symptomatic relief through antihistamines and corticosteroids, has proven to be insufficient for many allergy sufferers. Such medications provide temporary respite from symptoms but do not address the root causes of allergies. As allergies become more prevalent, there is a growing demand for treatments that offer lasting relief and a potential cure. Allergy vaccines, which work by desensitizing the immune system to specific allergens, fit this bill perfectly.

The increasing prevalence of allergies places a substantial economic burden on healthcare systems and individuals alike. Allergy-related medical expenses, including doctor visits, medication costs, and time lost from work, add up significantly. The appeal of allergy vaccines lies in their potential to reduce these economic burdens by decreasing the need for frequent doctor visits and medications. Over time, they can provide an economically viable solution for managing allergies.

With allergies becoming more common, the patient pool for allergy vaccines is expanding. Patients are now more inclined to explore long-term treatment options that offer hope for a life less constrained by allergies. This increased patient pool contributes directly to the growth of the allergy vaccine market.

In response to the growing demand, researchers and pharmaceutical companies are continually innovating and refining allergy vaccines. These advancements aim to improve the safety, efficacy, and convenience of allergen immunotherapy. For instance, sublingual immunotherapy (SLIT), which involves administering vaccines via tablets or drops under the tongue, is gaining popularity due to its ease of use and reduced risk of adverse reactions.

Demand for Long-Term Allergy Management

Allergies are a persistent and growing concern, affecting millions worldwide. As allergy rates continue to rise, so does the demand for long-term solutions that go beyond the short-term relief provided by antihistamines and corticosteroids. This demand for sustainable allergy management is a pivotal factor in the expansion of the global allergy vaccine market.

Allergic conditions, including allergic rhinitis, asthma, food allergies, and eczema, are becoming more prevalent across the globe. These allergies can be triggered by a variety of factors, including environmental changes, genetics, and lifestyle shifts. As a result, an ever-increasing number of individuals are seeking more effective ways to manage their allergic conditions.

Traditional allergy medications, such as antihistamines and corticosteroids, offer temporary relief from allergy symptoms. While these medications are valuable for alleviating discomfort, they do not address the root causes of allergies. This leaves patients in a never-ending cycle of managing symptoms rather than addressing the underlying problem.

Allergy vaccines, also known as allergen immunotherapy, offer a distinct advantage by providing long-term solutions for allergy sufferers. These vaccines work by desensitizing the immune system to specific allergens, thereby reducing the severity of allergic reactions and, in some cases, offering a potential cure. The promise of a life with fewer or no allergies is a significant draw for individuals who are tired of relying on short-term relief.

Allergies come with a substantial economic burden. The costs of doctor visits, allergy medications, and missed work due to allergy-related issues can add up significantly. Allergy vaccines, while initially an investment, can reduce these ongoing expenses. Over time, they offer an economically viable solution for individuals seeking long-term relief and a better quality of life.

Allergies are not confined to a specific age group; they affect people of all ages. With allergies becoming increasingly common, a wider range of age groups is seeking long-term solutions to their allergy woes. This expanding patient pool contributes directly to the growth of the allergy vaccine market.

Advancements in Treatment Methods

Allergies have become an increasingly common global health issue, affecting people of all ages. In response to the rising demand for more effective and lasting allergy management, advancements in treatment methods have taken center stage. These innovations are a critical driving force behind the remarkable growth of the global allergy vaccine market.

Traditional approaches to allergy management primarily involve the use of antihistamines, corticosteroids, and avoidance strategies. These methods provide temporary symptom relief but do not address the underlying causes of allergies. As a result, individuals dealing with allergies often find themselves in a cycle of managing recurring symptoms without achieving a long-lasting solution.

Allergy vaccines, also known as allergen immunotherapy, are distinct in their ability to provide long-term solutions for allergy sufferers. These vaccines work by desensitizing the immune system to specific allergens, thereby reducing the severity of allergic reactions and, in some cases, offering a potential cure. They offer a lifeline to individuals who seek a life less constrained by allergies, offering the prospect of enduring relief.

Advancements in treatment methods have led to refinements in the formulation of allergy vaccines. Researchers and pharmaceutical companies have been working tirelessly to improve the safety and efficacy of allergen immunotherapy. Innovations include the use of modified allergens, which reduce the risk of adverse reactions, and novel delivery methods such as sublingual immunotherapy (SLIT).

Sublingual immunotherapy, or SLIT, is a groundbreaking innovation in the world of allergy vaccines. It involves administering the vaccine through tablets or drops placed under the tongue. This approach offers several advantages, including enhanced patient compliance, as it eliminates the need for frequent injections and reduces the risk of adverse reactions associated with traditional subcutaneous immunotherapy (SCIT).

Advancements in treatment methods have also paved the way for personalized medicine approaches in allergy management. By tailoring allergen immunotherapy to the specific needs of individual patients, healthcare providers can optimize treatment effectiveness. Personalized treatment plans can increase the chances of successful long-term allergy management.

Pharmaceutical companies and research institutions are heavily investing in the research and development of allergy vaccines. These initiatives aim to develop more effective vaccines, optimize existing treatments, and explore new treatment approaches. As a result, the market benefits from a continuous stream of innovative solutions.

Rising Awareness of Allergen Immunotherapy

Allergies are increasingly prevalent, affecting millions of individuals across the globe. In the quest for more effective and long-lasting allergy management, awareness of allergen immunotherapy, or allergy vaccines, is on the rise. This heightened awareness is not only transforming the way individuals perceive allergy treatment but also serving as a catalyst for the growth of the global allergy vaccine market.

Allergic conditions, ranging from hay fever to food allergies and asthma, have become an epidemic. A combination of factors, including genetics, environmental changes, and lifestyle shifts, has contributed to the escalating prevalence of allergies. This widespread issue has compelled individuals to seek better solutions for their allergy management.

Conventional approaches to allergy management, such as antihistamines and corticosteroids, offer symptomatic relief but do not address the root causes of allergies. Individuals are increasingly looking for treatments that go beyond temporary fixes and provide lasting relief. Allergy vaccines offer precisely that, desensitizing the immune system to specific allergens and potentially offering a cure.

Rising awareness has shifted the public's perception of allergy management from mere relief to disease prevention. Individuals and healthcare providers now recognize that allergen immunotherapy addresses the underlying causes of allergies, making it a powerful tool for preventing future allergic reactions. This newfound understanding is driving individuals toward allergen immunotherapy.

Informed patients are empowered patients. As more individuals learn about allergen immunotherapy, they are better equipped to engage in meaningful conversations with healthcare providers and make informed decisions about their allergy management. This empowerment contributes to the growth of the market as patients seek allergy vaccines as a viable long-term solution.

Government agencies and public health organizations play a pivotal role in raising awareness about allergen immunotherapy. Educational campaigns and initiatives are disseminating information about the efficacy and safety of these treatments, contributing to a broader understanding of their benefits.

Key Market Challenges

Limited Insurance Coverage

While awareness of the benefits of allergen immunotherapy is growing, insurance coverage for these treatments remains limited in many regions. This places a financial burden on patients, making it more difficult for them to access long-term allergy management through allergy vaccines.

Lengthy Treatment Process

Allergen immunotherapy is a long-term commitment. It typically involves a build-up phase and a maintenance phase, which can span several months or even years. Patient adherence to the treatment plan is crucial for its success, but the lengthy process can be challenging for some individuals, leading to dropouts.

Allergen Selection and Personalization

Allergen selection and personalization are critical for the efficacy of allergen immunotherapy. Identifying the specific allergens causing an individual's allergic reactions is essential for tailoring the treatment. However, this process can be time-consuming and costly, and it may not always yield the desired results.

Key Market Trends

Modified Allergens

The development of modified allergens is another exciting trend in the field. By modifying allergens to reduce their allergenicity while maintaining their immunogenicity, researchers are working to create safer and more effective allergy vaccines. These modified allergens may help minimize adverse reactions during treatment.

Sublingual Immunotherapy (SLIT)

Sublingual immunotherapy, or SLIT, is gaining popularity as a more convenient and potentially safer method for administering allergy vaccines. SLIT involves placing allergen-containing tablets or drops under the tongue, reducing the need for injections and decreasing the risk of systemic side effects. This trend is likely to continue as more patients seek user-friendly treatment options.

Combination Therapies

Combination therapies, involving a mix of multiple allergen immunotherapy treatments or allergen immunotherapy with other allergy management methods, are emerging as a potential solution to enhance the efficacy of allergy vaccines. This trend may provide a more comprehensive approach to allergy treatment.

Segmental Insights

Allergy Type Insights

Based on the category of Allergy Type, the Tree Pollen Hypersensitivity segment is poised to capture a substantial market share in the Global Allergy Vaccine Market during the forecast period for several compelling reasons. Firstly, the increasing prevalence of tree pollen allergies worldwide, owing to climate changes and environmental factors, is expected to drive the demand for effective allergy vaccines. Additionally, heightened awareness and the importance of preventative healthcare measures are encouraging individuals to seek immunotherapy solutions, which include tree pollen hypersensitivity vaccines. Moreover, advancements in vaccine formulation and administration techniques are enhancing the overall efficacy and patient compliance, further supporting the growth of this market segment. In sum, the Tree Pollen Hypersensitivity segment is well-positioned to flourish in the global allergy vaccine market, meeting the rising demand for allergy management solutions and contributing to improved public health outcomes.

Vaccine Type Insights

The House Dust Mite Allergy Vaccine is anticipated to secure a substantial market share in the Global Allergy Vaccine Market throughout the forecast period for several compelling reasons. Firstly, house dust mite allergies are prevalent and persistent, affecting a significant portion of the global population. This enduring demand for effective allergy management is expected to propel the adoption of house dust mite allergy vaccines. Secondly, as consumers become increasingly health-conscious and proactive in seeking preventive healthcare solutions, the need for long-term allergy management options like vaccines is on the rise. Furthermore, ongoing research and development efforts have led to improvements in vaccine formulations and delivery methods, enhancing both the safety and effectiveness of these vaccines. In summary, the House Dust Mite Allergy Vaccine is well-positioned to gain a substantial market share, addressing the persistent demand for allergy management and contributing to overall improvements in public health.

Regional Insights

North America is poised to dominate the Global Allergy Vaccine Market for several compelling reasons. Firstly, the region exhibits a high prevalence of allergic disorders, including pollen allergies, dust mite allergies, and food allergies, leading to an ever-growing demand for effective allergy management solutions. Secondly, North America boasts a well-established healthcare infrastructure and a strong emphasis on healthcare research and innovation, which has contributed to the development of advanced allergy vaccines. Additionally, a proactive approach to healthcare and increasing awareness among both healthcare providers and patients has created a robust market for allergy vaccines in North America. Furthermore, stringent regulatory standards and a favorable reimbursement environment provide a conducive landscape for market growth. In conclusion, North America's combination of high allergy prevalence, healthcare infrastructure, research initiatives, and supportive policies positions it to dominate the Global Allergy Vaccine Market during the forecast period.

Key Market Players

Stallergenes Greer PLC

Allergy Therapeutics PLC

HAL Allergy BV

Jubilant HollisterStier Allergy

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd

Dermapharm AG

Merck KGaA

Aimmune Therapeutics Inc

Report Scope:

In this report, the Global Allergy Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Allergy Vaccine Market, By Allergy Type:

• Allergic Asthma
• Cat Dander Allergy
• Grass Pollen Hypersensitivity
• Peanut Hypersensitivity
• Seasonal Allergic Rhinitis
• Tree Pollen Hypersensitivity

Allergy Vaccine Market, By Vaccine Type:

• Cat Allergy Vaccine
• House Dust Mite Allergy Vaccine
• Injectable MPL Allergy Vaccine
• Peanut Allergy Vaccine
• Ragweed Allergy Immunotherapy Vaccine

Allergy Vaccine Market, By Application:

• HIV
• Oncology
• Respiratory

Allergy Vaccine Market, By End User:

• Homecare
• Hospitals
• Specialty Clinics
• Others

Allergy Vaccine Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Allergy Vaccine Market.

Available Customizations:

• Global Allergy Vaccine market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Allergy Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Allergy Type (Allergic Asthma, Cat Dander Allergy, Grass Pollen Hypersensitivity, Peanut Hypersensitivity, Seasonal Allergic Rhinitis, Tree Pollen Hypersensitivity)
  • 5.2.2. By Vaccine Type (Cat Allergy Vaccine, House Dust Mite Allergy Vaccine, Injectable MPL Allergy Vaccine, Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine)
  • 5.2.3. By Application (HIV, Oncology, Respiratory)
  • 5.2.4. By End User (Homecare, Hospitals, Specialty Clinics, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2022)
• 5.3. Product Market Map
  • 5.3.1. By Allergy Type
  • 5.3.2. By Vaccine Type
  • 5.3.3. By Application
  • 5.3.4. By End User
  • 5.3.5. By Region

6. North America Allergy Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Allergy Type (Allergic Asthma, Cat Dander Allergy, Grass Pollen Hypersensitivity, Peanut Hypersensitivity, Seasonal Allergic Rhinitis, Tree Pollen Hypersensitivity)
  • 6.2.2. By Vaccine Type (Cat Allergy Vaccine, House Dust Mite Allergy Vaccine, Injectable MPL Allergy Vaccine, Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine)
  • 6.2.3. By Application (HIV, Oncology, Respiratory)
  • 6.2.4. By End User (Homecare, Hospitals, Specialty Clinics, Others)
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Allergy Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Allergy Type
      • 6.3.1.2.2. By Vaccine Type
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Allergy Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Allergy Type
      • 6.3.2.2.2. By Vaccine Type
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Allergy Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Allergy Type
      • 6.3.3.2.2. By Vaccine Type
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Allergy Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Allergy Type (Allergic Asthma, Cat Dander Allergy, Grass Pollen Hypersensitivity, Peanut Hypersensitivity, Seasonal Allergic Rhinitis, Tree Pollen Hypersensitivity)
  • 7.2.2. By Vaccine Type (Cat Allergy Vaccine, House Dust Mite Allergy Vaccine, Injectable MPL Allergy Vaccine, Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine)
  • 7.2.3. By Application (HIV, Oncology, Respiratory)
  • 7.2.4. By End User (Homecare, Hospitals, Specialty Clinics, Others)
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Allergy Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Allergy Type
      • 7.3.1.2.2. By Vaccine Type
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Allergy Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Allergy Type
      • 7.3.2.2.2. By Vaccine Type
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. France Allergy Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Allergy Type
      • 7.3.3.2.2. By Vaccine Type
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Allergy Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Allergy Type
      • 7.3.4.2.2. By Vaccine Type
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Allergy Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Allergy Type
      • 7.3.5.2.2. By Vaccine Type
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Allergy Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Allergy Type (Allergic Asthma, Cat Dander Allergy, Grass Pollen Hypersensitivity, Peanut Hypersensitivity, Seasonal Allergic Rhinitis, Tree Pollen Hypersensitivity)
  • 8.2.2. By Vaccine Type (Cat Allergy Vaccine, House Dust Mite Allergy Vaccine, Injectable MPL Allergy Vaccine, Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine)
  • 8.2.3. By Application (HIV, Oncology, Respiratory)
  • 8.2.4. By End User (Homecare, Hospitals, Specialty Clinics, Others)
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Allergy Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Allergy Type
      • 8.3.1.2.2. By Vaccine Type
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. Japan Allergy Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Allergy Type
      • 8.3.2.2.2. By Vaccine Type
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. India Allergy Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Allergy Type
      • 8.3.3.2.2. By Vaccine Type
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. Australia Allergy Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Allergy Type
      • 8.3.4.2.2. By Vaccine Type
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. South Korea Allergy Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Allergy Type
      • 8.3.5.2.2. By Vaccine Type
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Allergy Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Allergy Type (Allergic Asthma, Cat Dander Allergy, Grass Pollen Hypersensitivity, Peanut Hypersensitivity, Seasonal Allergic Rhinitis, Tree Pollen Hypersensitivity)
  • 9.2.2. By Vaccine Type (Cat Allergy Vaccine, House Dust Mite Allergy Vaccine, Injectable MPL Allergy Vaccine, Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine)
  • 9.2.3. By Application (HIV, Oncology, Respiratory)
  • 9.2.4. By End User (Homecare, Hospitals, Specialty Clinics, Others)
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Allergy Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Allergy Type
      • 9.3.1.2.2. By Vaccine Type
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Allergy Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Allergy Type
      • 9.3.2.2.2. By Vaccine Type
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Allergy Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Allergy Type
      • 9.3.3.2.2. By Vaccine Type
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Allergy Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Allergy Type (Allergic Asthma, Cat Dander Allergy, Grass Pollen Hypersensitivity, Peanut Hypersensitivity, Seasonal Allergic Rhinitis, Tree Pollen Hypersensitivity)
  • 10.2.2. By Vaccine Type (Cat Allergy Vaccine, House Dust Mite Allergy Vaccine, Injectable MPL Allergy Vaccine, Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine)
  • 10.2.3. By Application (HIV, Oncology, Respiratory)
  • 10.2.4. By End User (Homecare, Hospitals, Specialty Clinics, Others)
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Allergy Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Allergy Type
      • 10.3.1.2.2. By Vaccine Type
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Allergy Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Allergy Type
      • 10.3.2.2.2. By Vaccine Type
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Allergy Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Allergy Type
      • 10.3.3.2.2. By Vaccine Type
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User
  • 10.3.4. Kuwait Allergy Vaccine Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Allergy Type
      • 10.3.4.2.2. By Vaccine Type
      • 10.3.4.2.3. By Application
      • 10.3.4.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Product Offerings
• 14.3. Recent Developments
• 14.4. Financials (As Reported)
• 14.5. Key Personnel
• 14.6. SWOT Analysis
  • 14.6.1. Stallergenes Greer PLC
  • 14.6.2. Allergy Therapeutics PLC
  • 14.6.3. HAL Allergy BV
  • 14.6.4. Jubilant HollisterStier Allergy
  • 14.6.5. Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
  • 14.6.6. Dermapharm AG
  • 14.6.7. Merck KGaA
  • 14.6.8. Aimmune Therapeutics Inc

15. Strategic Recommendations

16. About Us & Disclaimer